For GLP-1 analogues and DPP-4 inhibitors, a baseline assessment of pancreatic risk factors (e.g., triglyceride level, gallbladder status, alcohol use history) can be performed before initiating therapy, especially in patients with preexisting metabolic syndrome (Tenner et al., 2024). Here, GLP1R is linked to metabolic syndrome.